SCHEMBL6329403

SCHEMBL6329403

CC/C(Nc1cccc(C(C)(C)N)c1)=C1/C(=O)Nc2cc(OC)c(OC)cc21

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 7/20 0.41
RET P07949 3/20 0.41
BRD2 P25440 2/20 0.41
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
STK10 O94804 2/20 0.39
SLK Q9H2G2 2/20 0.39
HTT P42858 1/20 0.37
RXFP1 Q9HBX9 2/20 0.37
PDPK1 O15530 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
RECQL P46063 1/20 0.37
KMT2A Q03164 1/20 0.37
EGFR P00533 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6337186 0.89 RET (0.43) BRD4RETBRD2PDPK1EGFR
SCHEMBL6333341 0.85 RET (0.54) BRD4RETBRD2KDM4EALDH1A1
SCHEMBL6333335 0.85 RET (0.54) BRD4RETBRD2KDM4EALDH1A1
SCHEMBL5786304 0.83 RET (0.45) BRD4RETBRD2LMNASMN1; SMN2
SCHEMBL6336774 0.83 RET (0.42) BRD4RETBRD2PDPK1EGFR
SCHEMBL6331367 0.82 MOGAT2 (0.46) BRD4RETMEN1KMT2AEGFR
SCHEMBL6331361 0.82 MOGAT2 (0.46) BRD4RETMEN1KMT2AEGFR
SCHEMBL6329095 0.81 RET (0.44) BRD4RETBRD2PDPK1EGFR
SCHEMBL6329107 0.81 RET (0.44) BRD4RETBRD2PDPK1EGFR
SCHEMBL6329408 0.81 ACHE (0.41) RETLMNASMN1; SMN2HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-01-13 US disclosed
US-6794395-B1 Substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments CCNE1, CDK1, CCNI BRD4 439/4885RET 154/4885BRD2 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.